The word "cancer" covers more than 200 biologically distinct diseases, which is why the question "are there trials for my cancer?" has wildly different answers depending on whether you're asking about EGFR-mutated NSCLC (hundreds of options), ampullary carcinoma (a handful), or KRAS G12C-mutated pancreatic cancer (actively being addressed for the first time). What's changed in 2026 isn't just the number of trials — it's that the infrastructure for matching patients to trials has finally caught up. Tumor-agnostic approvals mean your biomarker matters more than your organ of origin. Liquid biopsy means molecular eligibility can be confirmed from a blood draw. And mRNA cancer vaccines entering Phase 3 mean we're genuinely at the beginning of something new, not the tail end of the checkpoint inhibitor wave.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Over 8,000 oncology studies are actively recruiting on ClinicalTrials.gov in 2026 — spanning checkpoint inhibitors, antibody-drug conjugates, CAR-T cell therapy, KRAS inhibitors, personalized mRNA cancer vaccines (mRNA-4157/V940 now in Phase 3 after a 44% reduction in recurrence in adjuvant melanoma), and more than a dozen novel mechanisms in Phase 1. This guide explains the treatment categories driving the most trial activity, how to find studies for specific cancer types, what molecular profiling you need before searching, and what enrollment realistically involves for patients and caregivers in 2026.
ClinicalMetric Analysis
- Tumor-agnostic approvals have inverted the eligibility calculus. Pembrolizumab for MSI-H/dMMR tumors, larotrectinib and entrectinib for NTRK fusions, and selpercatinib for RET fusions can all apply to your cancer regardless of where it originated. In 2026, this matters for trial eligibility too: many basket trials enroll by biomarker, not histology. A patient with an NTRK fusion in a salivary gland cancer may have more trial options than one with a more common cancer type that lacks an actionable marker. Comprehensive genomic profiling — not standard pathology panels — is the prerequisite.
- The mRNA-4157/V940 melanoma result is genuinely important but frequently misquoted. The 44% reduction in recurrence or death versus pembrolizumab alone (in adjuvant high-risk melanoma, Phase 2b KEYNOTE-942) is a dramatic number for an early trial. But it's a Phase 2b result in a specific population, with a specific manufacturing model (individualized neoantigen selection requires weeks of tumor sequencing per patient). The commercial and logistical questions — how many centers can actually produce these at scale, and for which cancer types — are still open. Phase 3 in melanoma and NSCLC are now the real test.
- Community oncology trial access is better than most patients assume — and worth asking for explicitly. Major academic centers are not the only places running NCTN trials. ECOG-ACRIN and SWOG explicitly prioritize community oncology enrollment for many Phase 2/3 studies. Patients in smaller cities or rural areas who assume trial access requires traveling to an NCI Comprehensive Cancer Center should ask their local oncologist which NCTN studies their practice is a member of. The answer is often more than they expect.
The Infrastructure Behind Cancer Trials in 2026
More than 1.9 million new cancer cases will be diagnosed in the United States in 2026, and an estimated 600,000 people will die from the disease. The gap between those numbers and what was achievable a decade ago is directly attributable to clinical trial-validated advances: pembrolizumab alone has improved survival in lung, head and neck, bladder, endometrial, cervical, MSI-H solid tumors, and melanoma. KRAS was considered undruggable for 30 years; sotorasib and adagrasib, both approved since 2021, changed that calculus in NSCLC and are now being tested in colorectal, pancreatic, and biliary cancers.
The NCI's National Clinical Trials Network (NCTN) coordinates the largest government-funded cancer trial network — hundreds of Phase 2 and 3 studies running through ECOG-ACRIN, SWOG, Alliance, and the Children's Oncology Group. Industry-sponsored trials run simultaneously through academic cancer centers and an expanding community oncology network. For patients, what matters is that NCTN trials are often accessible at community oncology practices, not just major academic centers — which matters enormously for patients who can't easily travel to an NCI Comprehensive Cancer Center.
The Four Drug Classes Driving Most 2026 Oncology Trial Activity
Checkpoint inhibitors and next-generation immunotherapy
PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab) remain the backbone of immuno-oncology. But 2026 trials are focused on what comes after and what comes with them. Nivolumab + relatlimab (dual PD-1/LAG-3 blockade, approved for melanoma in 2022 as Opdualag, ORR 43% vs 33% for nivolumab monotherapy) is now being tested in NSCLC and other tumors. TIGIT inhibitors — domvanalimab, tiragolumab — are in pivotal trials despite early mixed results. The principle is clear: combination checkpoint blockade works for some patients, and the clinical question in 2026 is identifying who those patients are by biomarker.
Antibody-drug conjugates (ADCs)
ADCs are the fastest-growing drug class in oncology and the one with the most active pivotal trial portfolio. Trastuzumab deruxtecan (T-DXd/Enhertu) is in 10+ active Phase 3 trials across HER2-expressing tumors — breast, gastric, NSCLC, cervical, colorectal. Its DESTINY-Breast04 data (PFS 9.9 vs 5.1 months vs chemotherapy in HER2-low metastatic breast cancer) created an entirely new biomarker-defined patient population. Sacituzumab govitecan (TROP2-targeted), mirvetuximab soravtansine (FRα-targeted, ovarian cancer), and a dozen next-generation ADCs with improved payloads and linker chemistry are moving through Phase 1/2. The bystander effect — where released cytotoxin kills neighboring antigen-negative cells — makes modern ADCs active even in heterogeneous tumors.
CAR-T cell therapy: six approvals and counting
Six CAR-T products are FDA-approved for leukemia, lymphoma, and myeloma — all in hematologic cancers. Extending this to solid tumors has been the field's central challenge for years. The tumor microenvironment suppresses T-cell activity, antigen heterogeneity allows escape, and T-cell exhaustion limits durability. In 2026, the strategies being tested include armored CAR-T cells that secrete their own cytokines (to survive in hostile microenvironments), logic-gated dual-antigen CAR-T constructs (requiring two tumor antigens to activate, reducing on-target/off-tumor toxicity), and allogeneic "off-the-shelf" CAR-T from healthy donor T-cells. Phase 1 data for solid tumor CAR-T in glioblastoma, sarcoma, and mesothelioma are generating cautious optimism.
Personalized mRNA cancer vaccines: Phase 3 has arrived
mRNA-4157/V940 (Moderna/Merck) encodes up to 34 neoantigens unique to each patient's tumor — mutations identified by whole-exome sequencing after surgical resection. Combined with pembrolizumab in resected high-risk melanoma, it showed a 44% reduction in recurrence or death versus pembrolizumab alone (Phase 2b KEYNOTE-942 data at ASCO 2023). Phase 3 trials are now enrolling in NSCLC, bladder cancer, and renal cell carcinoma. Each vaccine is manufactured individually per patient — the manufacturing timeline is approximately 6–8 weeks from tumor biopsy to infusion. This isn't a platform tweak; it's a fundamentally different paradigm for cancer treatment.
Finding the Right Trial: A Practical Framework
ClinicalTrials.gov is the authoritative registry, searchable by cancer type, location, phase, age, and prior treatment. Filtering by "Recruiting" status and adding your cancer type, stage, and prior regimens significantly narrows results. The NCI's cancer.gov trial finder adds patient-friendly language and a phone consultation option (1-800-4-CANCER). For patients at NCI-designated Comprehensive Cancer Centers, a patient navigator can do the initial search and pre-screen for eligibility — this service is free and dramatically reduces the time patients spend on the research themselves.
Disease-specific advocacy organizations often have the most current awareness of which trials are actually enrolling — Pancreatic Cancer Action Network (PanCAN), LUNGevity, ZERO Prostate Cancer, and Susan G. Komen have dedicated trial-matching resources and patient support lines. For rare tumors, these organizations are frequently the fastest path to relevant trial identification.
What Your Oncologist Needs From You Before Searching
Molecular profiling is now the entry requirement for a substantial proportion of cancer trials. Without a next-generation sequencing (NGS) panel result, you may be ineligible for the most targeted options. Key biomarkers that drive trial eligibility in 2026: EGFR, ALK, RET, KRAS G12C, NTRK, HER2 amplification/mutation, BRCA1/2 (germline and somatic), PIK3CA, BRAF V600E, MSI/MMR status, PD-L1 CPS, and tumor mutational burden. The Foundation One CDx, Tempus xT, and Guardant360 CDx panels cover most of these from a single sample.
Performance status (ECOG scale 0–2) is a near-universal eligibility criterion. ECOG 0 means fully active; ECOG 1 means restricted in strenuous activity; ECOG 2 means ambulatory and capable of self-care, confined to bed less than 50% of waking hours. Most Phase 1/2 trials require ECOG 0–1. Some Phase 3 trials allow ECOG 0–2. This single variable excludes many patients who are otherwise good candidates — which is worth knowing before you assume you qualify.
What Enrollment Actually Involves
Screening typically takes 2–4 weeks and involves laboratory tests, imaging, and often a fresh or archival tumor biopsy for biomarker confirmation. Randomized trials assign patients to treatment arms by computer-generated random allocation — commonly experimental treatment plus standard care versus placebo plus standard care. Crossover provisions, which allow control-arm patients to receive the experimental treatment if their disease progresses, are now standard in most oncology trials.
Trial participation requires more frequent visits and blood draws than standard care. Data Safety Monitoring Boards (DSMBs) review interim data on a defined schedule and can stop a trial early for overwhelming benefit or unacceptable harm. Patients can withdraw at any time without affecting their access to standard care — this is a right, not a formality.
Key Takeaways
- Over 8,000 cancer trials are actively recruiting in 2026 — immunotherapy, ADCs, CAR-T, personalized vaccines, targeted therapy, and combination regimens across all major cancer types.
- NGS molecular profiling is essential before searching. Without EGFR, ALK, KRAS, BRCA, MSI, PD-L1, and TMB data, you may miss eligibility for the most targeted options.
- mRNA-4157/V940 (Moderna/Merck) is in Phase 3 across NSCLC, bladder, and renal cancer after a 44% reduction in melanoma recurrence — the first individually manufactured cancer therapeutic at pivotal scale.
- NCTN trials (ECOG-ACRIN, SWOG, Alliance) are often accessible at community oncology practices — not only at major academic centers.
- Disease-specific advocacy organizations frequently have the most current knowledge of which trials are actively enrolling versus on hold — their trial-matching services can shortcut weeks of independent searching.